AMPLY Discovery is a UK biotech turning the 98% of the genome largely ignored by drug developers into a pipeline of first-in-class therapeutics. Six AI engines. Two wet labs. One closed loop between silicon and bench.
We've just announced a strategic investment from Keeps Biomed (Keeps Biopharma, South Korea) and a partnership to explore oncology collaboration — plus we've appointed Oliver Rausch as AMPLY's new CSO.
These are pivotal moments in AMPLY Discovery's nascent development: our approach is moving from interesting towards partner-ready — mining multi-omic data (including non-coding regions of the genome) and backing it up with iterative wet-lab validation so our partners can make real go/no-go decisions. AI as the product isn't the focus for AMPLY — we believe that the techbio winners will eventually be the teams that can turn computation into credible, experimentally validated programmes with clear translational logic.
This key hire of Oliver and this partnership put AMPLY in an incredible position to eventually be one of those next winners.
Each engine is a specialised tool that solves one part of the dark-genome problem — from finding the right target, to designing the molecule, to deciding what runs next at the bench.
Together, they form an integrated ML-discovery loop called TALON.
… in two world-class translational hubs. Continuously teaching the platform…
… so we can tackle critical diseases like Triple-Negative Breast Cancer and Multi-Drug-Resistant Tuberculosis.
Two antimicrobial-peptide programmes targeting drug-resistant respiratory infection. Two long non-coding RNA oligonucleotide programmes against hard-to-treat oncology indications.
Around half a million new MDR-TB cases emerge each year. First-line treatment failures push patients into multi-drug regimens lasting 9+ months with significant toxicity. Antimicrobial-peptide therapy offers a fundamentally different mechanism with low resistance liability, delivered directly to the site of infection via aerosol.
Stage · In VivoCystic fibrosis patients face chronic colonisation by Pseudomonas aeruginosa and resistant Staphylococcus species — pathogens against which conventional antibiotics are steadily losing ground. Inhaled peptide therapeutics deliver multi-mechanism activity at high local concentration, straight to the airways.
Stage · In VivoTNBC accounts for ~15–20% of breast cancers and lacks the three actionable receptors (HER2, ER, PR) that drive standard targeted therapies, leaving patients largely chemotherapy-dependent. Our oligos silence cancer-specific dependencies surfaced by HALLUX in the dark genome.
Stage · In Vitro POCAML carries a 5-year survival rate below 30% in older adults. Genetic heterogeneity and a thin pipeline of targeted options leave most patients reliant on intensive chemotherapy. Our platform surfaces subtype-specific lncRNA dependencies that open new therapeutic windows.
Stage · In Vitro POCAMPLY is led by operators with deep biotech, computational biology, and commercial experience — over 100 years combined across the founding management team and our scientific lead.
25+ years across financial asset management, predictive marketing, and computational biology. PhD in bioinformatics from Aberystwyth (2018), PDRA at QUB. Architect of the TALON platform.
25+ years of industry experience spanning technology licensing, corporate finance, and business development. Co-founded AMPLY out of Queen's University Belfast.
Former CSO of STORM Therapeutics; prior leadership at Cellzome (now GSK), UCB Pharma, and the NIHR. PhD, Institute of Cancer Research, London. Career spent moving molecules from discovery to clinic.
Strategic consultant, interim executive, and non-executive across BioPharma. Provides AMPLY with senior commercial guidance and board-level governance.
From wet-lab co-investigators to academic founders, translational clinicians, and industry consultants — these are the people behind the data.
World-leading computational biologist at QUB. Expert in transcriptomic, metagenomic, metataxonomic and phylogenomic data, applying ecological and evolutionary principles to microbial communities.
Postdoctoral Research Fellow at the Future Medicines Institute. PhD from QUB's Patrick G. Johnston Centre for Cancer Research, with publications in Molecular Pharmaceutics. Cancer pharmacology focus.
Researcher at the Patrick G. Johnston Centre for Cancer Research, QUB. Work focuses on death-domain receptor signalling, breast cancer biology, and the death-inducing signalling complex (DISC).
Synthetic drug synthesis and performance specialist with extensive hospital-based clinical background. Brings hands-on chemistry expertise to AMPLY's wet-lab and translational programmes.
Professor of Animal Science & Microbiology and Director of Research, School of Biological Sciences at QUB. Internationally recognised expert in microbial ecosystems and metagenomics; leads the global RUMEN Gateway consortium.
Voting member of the CLSI veterinary antimicrobial susceptibility standards subcommittee and the British Society for Antimicrobial Chemotherapy (BSAC). Provides AMPLY with biomedical commercial-translation expertise.
Professor of Immunology and Deputy Director of the Institute for Infection & Immunity at City St George's. Coordinator of the EU-funded EMI-TB vaccine consortium; specialist in TB, dengue, Buruli ulcer, and SARS-CoV-2 vaccine and immunotherapy programmes.
Researcher at the Institute for Infection & Immunity. Tuberculosis vaccine research, with collaborative work spanning the South African Tuberculosis Vaccine Initiative (SATVI) and the EMI-TB programme.
AMPLY is seed-stage and building relationships now with Series A–aligned investors, pharma and biotech partners, and potential delivery collaborators — with an eye on accelerating platform-derived programmes toward key preclinical inflection points.
If your network includes any of these, let's connect today.
“The thing that I love about the deep ocean is that every time you dive, every single time, you see something you've never seen.
And every once in a while you're going to see something that nobody has ever seen.
James Cameron — filmmaker & deep-sea explorer